



ASX ANNOUNCEMENT

Managing Director share loan repayment

- **Dr Bill Ketelbey, Actinogen Medical CEO & MD repays A\$360k Company loan to secure 9m Actinogen shares**

Sydney, 27 November 2019. Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to announce that Dr Bill Ketelbey has repaid a company loan of A\$360k to secure Actinogen shares relating to Dr Ketelbey's Class H and J long term incentive (LTI) rights.

As outlined in the FY19 annual report, Dr Ketelbey held 9m vested (Class H and J) and 3m unvested (Class I) shares (LTI rights). To secure the vested LTI rights, Dr Ketelbey has paid off the Company loan of A\$360k in relation to 9m Actinogen shares held in his name. Additionally, Dr Ketelbey has subsequently transferred the 9m Actinogen shares from his name into the names of John William and Jane Ketelbey as trustees of the Kaleidoscope Superannuation Fund (refer to attached Appendix 3Y).

Dr Bill Ketelbey said: "I am delighted to secure these Actinogen shares at this time. We are making great progress with the development of Xanamem and remain well positioned to initiate the next series of Xanamem studies on the back of the recent outstandingly positive trial results."

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

Investor and Media Enquiries

Arthur Chan
WE Communications
P: +61 2 9237 2805
E: arthurc@we-worldwide.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotechnology company focused on innovative approaches to treating cognitive decline that occurs in chronic neurological and metabolic diseases. Actinogen Medical is in Phase 2 development of its lead compound Xanamem, a promising new therapy for Alzheimer's disease, a condition with multibillion-dollar market potential and material human impact. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn and is projected to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia. In addition, Actinogen is currently planning an expanded clinical development program for Xanamem in cognitive impairment in mood disorders and schizophrenia. In the US alone, the collective economic costs of mood disorders and schizophrenia are estimated to exceed \$550bn, with the burden increasing every year. The cognitive dysfunction associated with these conditions is significantly debilitating for affected patients, with a substantial unmet medical need for novel, improved treatments.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11 β -HSD1 enzyme in the brain. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory. The 11 β -HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease, mood disorders and schizophrenia.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr John William Ketelbey
Date of last notice	13 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect 3. Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	2. Spouse – Mrs Jane Ketelbey 3. John William Ketelbey & Jane Ketelbey <Kaleidoscope Superannuation Fund> - beneficiary
Date of change	22 November 2019
No. of securities held prior to change	1. 12,642,894 fully paid ordinary shares. 11,700,000 unlisted options exercisable at \$0.085 each on or before 27 November 2023 and subject to vesting conditions. 1,645,718 listed options exercisable at \$0.06 each and expiring 31 March 2019. 2. 310,909 fully paid ordinary shares. 1,454 listed options exercisable at \$0.06 each and expiring 31 March 2019 3. Nil
Class	Fully paid ordinary shares
Number acquired	3. 9,000,000
Number disposed	1. 9,000,000

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
No. of securities held after change	<ol style="list-style-type: none"> 1. 3,642,894 fully paid ordinary shares. 11,700,000 unlisted options exercisable at \$0.085 each on or before 27 November 2023 and subject to vesting conditions. 1,645,718 listed options exercisable at \$0.06 each and expiring 31 March 2019. 2. 310,909 fully paid ordinary shares. 1,454 listed options exercisable at \$0.06 each and expiring 31 March 2019 3. 9,000,000 fully paid ordinary shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Transfer of fully paid ordinary shares from a direct holding into a superannuation fund. No change in beneficial ownership.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
---	-----

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.